Physician profile
David Filsoof
NPI 1861686354
$142,195.15
in general payments reported to CMS, 2019-2025
62 companies · $54K in 2025
The $54K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,288 · 2020: $5,901 · 2021: $6,161 · 2022: $5,343 · 2023: $28K · 2024: $41K · 2025: $54K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $104K · Food and Beverage: $15K · Travel and Lodging: $2,657 · Education: $48.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $104,466.19 |
| Food and Beverage | $15,330.85 |
| Travel and Lodging | $2,656.82 |
| Education | $48.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $60,861.88 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $22,306.74 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18,745.25 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14,898.31 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $4,825.04 | 2019-2025 | Accolade Sr, Lux-Dx Insertable Cardiac Monitor, Watchman Flx |
| Genentech USA, INC. | $4,500.60 | 2019-2021 | |
| Heartflow, INC. | $2,099.65 | 2022-2025 | Ffrct |
| Lilly USA, LLC | $1,852.87 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $1,450.65 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,251.41 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Janssen Pharmaceuticals, INC | $1,138.51 | 2019-2024 | Xarelto |
| Abbott Laboratories | $820.31 | 2019-2022 | |
| Pfizer INC. | $564.20 | 2019-2025 | |
| Esperion Therapeutics, INC. | $559.59 | 2020-2025 | Nexletol, Nexlizet |
| Edwards Lifesciences Corporation | $548.02 | 2019-2025 | Sapien 3 Ultra Resilia |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Filsoof listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.